OSE Immunotherapeutics Presentation at H.C. Wainwright Global Life Sciences Conference
23 févr. 2021 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, Feb. 23, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that Alexis Peyroles, Chief Executive Officer, will provide an overview of...
OSE Immunotherapeutics Announces Granting of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011
17 févr. 2021 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, Feb. 17, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that it has strengthened intellectual property rights for its...
OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank
15 févr. 2021 01h30 HE
|
OSE Immunotherapeutics
This loan will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in diseases with high unmet medical needs,Divided into three tranches including...
OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics
28 janv. 2021 12h00 HE
|
OSE Immunotherapeutics
OSE is advancing an "Immunotherapy 2.0" future by leveraging MAbSilico’s artificial intelligence-powered software solutions and professional services to accelerate and further optimize the development...
OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011
25 janv. 2021 01h30 HE
|
OSE Immunotherapeutics
Milestone as part of the collaborative program named EFFIMab marks continued clinical progressInterleukin-7 receptor antagonist (IL-7R) OSE-127/S95011 is currently in a Phase 2 clinical trial in...
OSE Immunotherapeutics Presentation at H.C. Wainwright BIOCONNECT 2021 Virtual Conference
05 janv. 2021 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, Jan. 05, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that Alexis Peyroles, Chief Executive Officer, will provide an overview of...
OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011
21 déc. 2020 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, Dec. 21, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced enrolment of the first patient in its Phase 2 clinical trial evaluating the...
OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of CoVepiT, its Second Generation COVID-19 Vaccine
18 déc. 2020 01h30 HE
|
OSE Immunotherapeutics
CoVepiT demonstrated generation of sentinel memory T cells with long-term protective effect against COVID-19 in preclinical and human ex vivo studiesCoVepiT targets 11 virus proteins to prepare for...
OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients Undergoing Renal Transplantation
03 déc. 2020 12h00 HE
|
OSE Immunotherapeutics
University Hospital of Nantes will sponsor and conduct the clinical trialOSE Immunotherapeutics will provide its FR104 productPost-transplant immune response is a key therapeutic issue for patients...
OSE Immunotherapeutics to Present at SITC Annual Meeting and at Additional International Immuno-Oncology Summits
09 nov. 2020 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, Nov. 09, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) has been invited to provide an update on its R&D programs in immuno-oncology at several...